Tauopathies Clinical Trials

24 clinical trials for Tauopathies across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503 — RECRUITING · PHASE1
• CW2IP2: Imaging and Diagnostic Assessments — RECRUITING · NA
• [18F]NIDF PET Imaging in Tau-related Diseases — RECRUITING
• Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A — RECRUITING · PHASE1
• Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15 — RECRUITING · PHASE1
• Tau PET/CT in Various Tau-Related Disease Patients — RECRUITING
• Neurodegenerative Diseases Progression Markers (MARKERS-NDD) — RECRUITING
• A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) — ACTIVE_NOT_RECRUITING · PHASE3
• A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation — COMPLETED · PHASE2
• An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease — TERMINATED · PHASE2
• Validation of Blood Biomarkers for Alzheimer's Disease — COMPLETED · NA
• A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease — COMPLETED · PHASE1
• Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems — COMPLETED · NA
• CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease — COMPLETED
• Harmony at Home: A Pilot Telehealth Program for Rural ADRD Caregivers — COMPLETED · NA
• Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation — WITHDRAWN · PHASE2
• A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants — OTHER · PHASE1
• A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population — COMPLETED · NA
• A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 — COMPLETED · PHASE2
• Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations — COMPLETED · PHASE2
• A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects — COMPLETED · PHASE1
• Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects — COMPLETED · PHASE1
• COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE — COMPLETED
• The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD — OTHER

Refine this search